TY - JOUR
T1 - The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis
AU - Novack, Deborah Veis
AU - Yin, Li
AU - Hagen-Stapleton, Amanda
AU - Schreiber, Robert D.
AU - Goeddel, David V.
AU - Ross, F. Patrick
AU - Teitelbaum, Steven L.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - The prototranscription factor p100 represents an intersection of the NF-κB and IκB families, potentially serving as both the precursor for the active NF-κB subunit p52 and as an IκB capable of retaining NF-κB in the cytoplasm. NF-κB-inducing kinase (NIK) controls processing of p100 to generate p52, and thus NIK-deficient mice can be used to examine the biological effects of a failure in such processing. We demonstrate that treatment of wild-type osteoclast precursors with the osteoclastogenic cytokine receptor activator of NF-κB ligand (RANKL) increases both expression of p100 and its conversion to p52, resulting in unchanged net levels of p100. In the absence of NIK, p100 expression is increased by RANKL, but its conversion to p52 is blocked, leading to cytosolic accumulation of p100, which, acting as an IκB protein, binds NF-κB complexes and prevents their nuclear translocation. High levels of unprocessed p100 in osteoclast precursors from NIK-/- mice or a nonprocessable form of the protein in wild-type cells impair RANKL-mediated osteoclastogenesis. Conversely, p100-deficient osteoclast precursors show enhanced sensitivity to RANKL. These data demonstrate a novel, biologically relevant means of regulating NF-κB signaling, with upstream control and kinetics distinct from the classical IκBα pathway.
AB - The prototranscription factor p100 represents an intersection of the NF-κB and IκB families, potentially serving as both the precursor for the active NF-κB subunit p52 and as an IκB capable of retaining NF-κB in the cytoplasm. NF-κB-inducing kinase (NIK) controls processing of p100 to generate p52, and thus NIK-deficient mice can be used to examine the biological effects of a failure in such processing. We demonstrate that treatment of wild-type osteoclast precursors with the osteoclastogenic cytokine receptor activator of NF-κB ligand (RANKL) increases both expression of p100 and its conversion to p52, resulting in unchanged net levels of p100. In the absence of NIK, p100 expression is increased by RANKL, but its conversion to p52 is blocked, leading to cytosolic accumulation of p100, which, acting as an IκB protein, binds NF-κB complexes and prevents their nuclear translocation. High levels of unprocessed p100 in osteoclast precursors from NIK-/- mice or a nonprocessable form of the protein in wild-type cells impair RANKL-mediated osteoclastogenesis. Conversely, p100-deficient osteoclast precursors show enhanced sensitivity to RANKL. These data demonstrate a novel, biologically relevant means of regulating NF-κB signaling, with upstream control and kinetics distinct from the classical IκBα pathway.
KW - Bone remodeling/physiology
KW - Cultured cells/physiology
KW - MAP kinase kinase kinases
KW - Mice knockout
KW - Murine RANKL
UR - http://www.scopus.com/inward/record.url?scp=0042386014&partnerID=8YFLogxK
U2 - 10.1084/jem.20030116
DO - 10.1084/jem.20030116
M3 - Article
C2 - 12939342
AN - SCOPUS:0042386014
SN - 0022-1007
VL - 198
SP - 771
EP - 781
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 5
ER -